CureVac

GSK's mRNA flu vaccine finally bests tricky B strains in phase 2

After an initial defeat against the biggest barrier to mRNA flu vaccines, GSK has returned with a reformulated candidate that has delivered the goods.

James Waldron Sep 12, 2024 4:52am

change direction new plan alter arrows move reprioritize

CureVac gains $430M GSK vaccine contract, loses 30% of staff

Jul 3, 2024 5:00am

Xaira, Anthos, CureVac & more—Chutes & Ladders

Apr 26, 2024 8:30am

Road block challenges clinical hold problems

CureVac, chasing Moderna mRNA flu shot, hits similar problems

Apr 4, 2024 9:30am

CureVac touts COVID-19 vax data despite adverse events

Jan 5, 2024 11:16am

Hand picking a red apple off a tree in an orchard

CureVac hand-picks mRNA flu vaccine but keeps data tucked away

Sep 12, 2023 10:45am